Royalty growth, a $332.8 million buyback and five new ENHANZE and Hypercon deals prompted the drug delivery company to lift revenue, adjusted EBITDA and EPS targets for 2026.
Halozyme Therapeutics raised its 2026 financial guidance after second-quarter revenue climbed 48% year over year to $481.0 million and royalty revenue rose 50% to $307.7 million. Adjusted EBITDA increased 46% to $328.8 million, non-GAAP diluted EPS reached $2.28 from $1.54, and the company said demand for ENHANZE partner products including VYVGART Hytrulo and DARZALEX SC continued to drive growth. Halozyme repurchased 4.8 million shares for $332.8 million in the quarter and said it has signed five ENHANZE and Hypercon collaboration agreements through July 2026 with Vertex, Oruka, GSK, Incyte and an undisclosed partner. The company now expects 2026 revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion and non-GAAP diluted EPS of $8.65 to $9.00.